Trade Filings
管理人 股票 申报文件 超级投资者
信号 机构买入 机构卖出 内部人活动 13D & 13G 监控 板块轮动
工具 股票筛选器 管理人筛选器 对比管理人 共识篮子 所有研究工具 数据 API
学习与 AI 学习 数据提问 AI 智能体
新闻 ★ 已保存
关于 关于我们 方法论 联系我们 免责声明
阅读器
数据方案

历史数据下载——随账户功能上线。

API 网关

对本站缓存数据提供免费只读JSON访问。

深色模式

🧭 引导视图
初次接触市场——对价格、收益率、年初至今涨幅、市值等概念感到陌生?我们在您浏览时以浅显易懂的方式解释每个术语,数据不变,帮助随时在线。

⚡ 专家视角
您已了解市场。只看数据——干净、快速、简洁,无多余解释。这是默认视图。

界面语言
证券记录 · 已归档季度

LLY

Eli Lilly and Company · Healthcare · Drug Manufacturers - General

1,233.5 -1.1% 市值 $1.16T 报价延迟(FMP) · 截至 Aug 25 22:08 UTC — 与下方申报数据相互独立

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024
22被追踪持有人
Δ持有人
112.43M持有股份
$101.75B报告持仓市值
+0新建仓位
−0清仓
计算方式说明 → 在研究台查询相关说明 →

所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q2 2024

持股变化趋势
季度持有人Δ股份报告持仓市值新增清仓
Q2 2026 193 +4 671.92M $804.91B +6 −1
Q1 2026 191 -3 666.59M $613.20B +1 −5
Q4 2025 193 +2 707.04M $758.81B +3
Q3 2025 27 -3 329.88M $251.63B +2 −6
Q2 2025 28 -1 307.45M $239.60B +2 −3
Q1 2025 26 0 140.32M $115.83B +1 −1
Q4 2024 26 +1 145.00M $111.91B +3 −2
Q3 2024 24 +2 109.89M $97.29B +2
Q2 2024 22 112.43M $101.75B
持有人数量
持有人 · Q2 2024
#管理人股份Δ股份价值其权重持有
1 Capital World Investors 21.81M $19.75B 3.2% n/c 1 SEC ↗
2 T. Rowe Price 20.65M $18.70B 2.2% n/c 1 SEC ↗
3 T. Rowe Price 20.65M $18.70B 2.2% n/c 1 SEC ↗
4 PRIMECAP Management 19.62M $17.76B 12.9% n/c 1 SEC ↗
5 Geode Capital Management (被动) 17.01M $15.35B 1.3% n/c 1 SEC ↗
6 Geode Capital Management (被动) 17.01M $15.35B 1.3% n/c 1 SEC ↗
7 Norges Bank (被动) 11.00M $9.96B 1.5% n/c 1 SEC ↗
8 Wellington Management 10.78M $9.76B 1.7% n/c 1 SEC ↗
9 Wellington Management 10.78M $9.76B 1.7% n/c 1 SEC ↗
10 Wellington Management 10.78M $9.76B 1.7% n/c 1 SEC ↗
11 Wellington Management 10.78M $9.76B 1.7% n/c 1 SEC ↗
12 Wellington Management 10.78M $9.76B 1.7% n/c 1 SEC ↗
13 Wellington Management 10.78M $9.76B 1.7% n/c 1 SEC ↗
14 Wellington Management 10.78M $9.76B 1.7% n/c 1 SEC ↗
15 Wellington Management 10.78M $9.76B 1.7% n/c 1 SEC ↗
16 Wellington Management 10.78M $9.76B 1.7% n/c 1 SEC ↗
17 Fisher Asset Management 4.89M $4.43B 1.9% n/c 1 SEC ↗
18 Arrowstreet Capital 1.61M $1.46B 1.3% n/c 1 SEC ↗
19 Tiger Global Management 930.00K $842.00M 3.9% n/c 1 SEC ↗
20 Adage Capital Partners 827.68K $749.37M 1.4% n/c 1 SEC ↗
21 Marshall Wace 789.56K $714.85M 1.0% n/c 1 SEC ↗
22 Marshall Wace 789.56K $714.85M 1.0% n/c 1 SEC ↗
23 Marshall Wace 789.56K $714.85M 1.0% n/c 1 SEC ↗
24 Millennium Management 532.04K $481.70M 0.4% n/c 1 SEC ↗
25 Citadel Advisors 500.83K $453.45M 0.5% n/c 1 SEC ↗
26 Citadel Advisors 500.83K $453.45M 0.5% n/c 1 SEC ↗
27 AQR Capital Management 474.55K $429.65M 0.7% n/c 1 SEC ↗
28 AQR Capital Management 474.55K $429.65M 0.7% n/c 1 SEC ↗
29 AQR Capital Management 474.55K $429.65M 0.7% n/c 1 SEC ↗
30 AQR Capital Management 474.55K $429.65M 0.7% n/c 1 SEC ↗
31 AQR Capital Management 474.55K $429.65M 0.7% n/c 1 SEC ↗
32 D. E. Shaw & Co. 237.22K $214.78M 0.3% n/c 1 SEC ↗
33 D. E. Shaw & Co. 237.22K $214.78M 0.3% n/c 1 SEC ↗
34 Two Sigma Investments 225.78K $204.42M 0.5% n/c 1 SEC ↗
35 Coatue Management 207.05K $187.46M 0.7% n/c 1 SEC ↗
36 Coatue Management 207.05K $187.46M 0.7% n/c 1 SEC ↗
37 Coatue Management 207.05K $187.46M 0.7% n/c 1 SEC ↗
38 Coatue Management 207.05K $187.46M 0.7% n/c 1 SEC ↗
39 Viking Global Investors 144.18K $130.53M 0.5% n/c 1 SEC ↗
40 Bridgewater Associates 95.74K $86.68M 0.5% n/c 1 SEC ↗
41 Dodge & Cox 45.98K $41.63M 0.0% n/c 1 SEC ↗
42 GAMCO Investors 35.83K $32.44M 0.4% n/c 1 SEC ↗
43 Gotham Asset Management 11.95K $10.82M 0.1% n/c 1 SEC ↗

"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。

新增买入方

本季度无新增被追踪买入方。

已清仓

本季度无被追踪的退出仓位。

全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 4,323 持有人, 762.84M 股份, $674.93B 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。

常见共同持仓

该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数,而非基本面关联。

内部人交易

公开市场买入 (P)

在我们的覆盖窗口内无内部人士公开市场买入记录。

公开市场卖出 (S)

Aug 17 Jonsson Patrik

Officer · 6.50K 股 · $7.64M

Aug 10 Zakrowski Donald A

Officer · 2.00K 股 · $2.37M

Aug 07 Hakim Anat

Officer · 5.00K 股 · $5.95M

授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论

受益所有权
Jul 23 SC 13G/A — LILLY ENDOWMENT INC

查看 SEC 原始申报文件 ↗

相关新闻
Aug 24 FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test ↗

The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…

Forbes
Aug 24 FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly ↗

The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…

WSJ
Aug 24 Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance ↗

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help ​identify signs of…

Reuters
Aug 24 Eli Lilly Launches Foundayo Weight-Loss Pill in U.K. ↗

The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…

WSJ
Aug 23 Eli Lilly launches oral weight-loss pill Foundayo in UK ↗

Eli Lilly said on Monday it has launched its oral pill, ​Foundayo, in the UK for weight ‌management and type 2…

Reuters
数据来源: 持股数据来源于已解析的13F普通股持仓(被追踪范围,变动对比集);内部人行为来自Form 3/4/5;重大持股来自Schedule 13D/13G;所有文件均链接至SEC EDGAR原始申报。 报告期: Q2 2024 · 方法论 · 通过API获取此数据